PARKINSONS DISEASE THERAPEUTICS MARKET ANALYSIS

Parkinsons Disease Therapeutics Market, By Drug Class (Levodopa, Dopamine agonists, MAO-B inhibitors, Anticholinergics, Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine, among Others)), By Route of Administration (Oral, Injectable, Nasal, Transdermal, Others (Rectal, Sublingual, among Others)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Global Parkinsons Disease Therapeutics Market: Key Developments

In February 2021, Adamas Pharmaceuticals, Inc., a company dedicated to developing and delivering medicines to people affected by neurological diseases, announced that it had received marketing authorization from the U.S. Food and Drug Administration (FDA) for a supplemental new drug application for GOCOVRI (amantadine) extended release capsules, gaining a second indication for the product as an adjunctive treatment to levodopa/carbidopa in Parkinson's disease patients.
In August 2020, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved NOURIANZ (istradefylline) as an add-on treatment to levodopa or carbidopa in adult patients with Parkinson’s disease (PD) experiencing ‘OFF’ episodes. ‘Off’ episodes are incapacitating periods of partial or total immobility that patients with advanced Parkinson's disease experience.

Global Parkinsons Disease Therapeutics Market: Key Trends

Collaboration Agreement signed by market players: The strong demand for medications for the treatment of Parkinson’s disease is having a significant impact on the global Parkinsons disease therapeutic market. The companies manufacturing drugs for the treatment of Parkinson’s disease are focused on expanding their global presence and product portfolio by using strategies such as agreements and collaborations with other market players. For instance, in 2021, Ipsen, a global mid-sized biopharmaceutical company, announced the signing of a licensing agreement with IRLAB, a Sweden-based research and development company. Under this agreement, Ipsen will have exclusive worldwide development and commercial rights to mesdopetam, a novel dopamine D3-receptor antagonist that is a potential treatment option for people with Parkinson's disease (PD) who have levodopa-induced dyskinesia (LID).